Expanded Genomic Screen.
Our broadest option, for people who want a wider baseline across inherited disease risk — up to 2,000 genes in one collection. Best chosen with clinical guidance, since broader screening returns more findings to interpret.
- Up to 2,000 genes · one collection
- Reviewed by our lab director
- Genetic counseling available
Panel
Up to 2,000 genes
Sample
Cheek swab at home
Review
Reviewed by our lab director
Price
From $950
What it screens for
A wider baseline across inherited risk.
Broader screening returns more findings to interpret — including variants of uncertain significance and secondary findings you may not have anticipated. That is why we recommend choosing this panel with clinical guidance.
Cancer predisposition
Includes the hereditary cancer genes covered by our focused panel — BRCA1, BRCA2 and beyond.
Cardiovascular risk
Includes the inherited cholesterol, cardiomyopathy and rhythm variants covered by our cardiovascular panel.
Other inherited conditions
A wider look across genes associated with other inherited conditions, giving you and your healthcare provider a broader baseline.
Who this is for
For people who want the widest single-collection answer.
A complete baseline
You want one comprehensive record of inherited risk while you are well, not after a diagnosis.
An unclear family pattern
When the family history points in several directions at once, breadth helps.
Working with a clinician or counselor
Best chosen with clinical guidance, because more results means more interpretation.
Is this panel right for you?
You want the broadest view of inherited risk in one test.
Your family history does not point to one clear category.
You have, or can get, clinical guidance for interpreting broad results.
You are planning a family and want to know what you carry.
Your doctor or a genetic counselor suggested testing.
You want results you can keep for life.
Answering yes to even one of these is a good reason to test now rather than after a diagnosis.
Before you order
Total price
From $950
One-time price, shown in full at checkout. No separate fee for the kit, return shipping or the healthcare provider order.
What's included
Kit to report
Cheek-swab kit with instructions, a prepaid FedEx overnight return label, the healthcare provider order, testing in our CLIA-certified lab and a report in your secure portal.
Who orders the test
A licensed healthcare provider
A licensed healthcare provider in our network reviews your request and places the order during checkout, at no extra cost. No referral needed.
Genetic counseling
Available
Genetic counseling is available with every panel — we recommend it in particular for the expanded panel.
The science
What the evidence says about getting tested.
Broad genomic screening changes the question from “is there a variant behind this diagnosis?” to “what should I know while I am healthy?” Population studies show a small but real share of healthy people carry a pathogenic variant in a medically actionable gene, and professional bodies such as ACMG maintain a defined list of secondary findings labs are recommended to report. The trade-off is equally documented: broad screens also return variants of uncertain significance, which is why clinical guidance belongs in the decision.
≈2%
of healthy people carry a pathogenic variant in a medically actionable gene in population sequencing studies.
Source: Population sequencing studies
≈80
genes on the ACMG secondary-findings list that laboratories are recommended to report.
Source: ACMG recommendations
2,000
genes in this screen — the broadest single-collection inherited-risk baseline we offer.
Source: MyPMC expanded panel
Some
broader screens return variants of uncertain significance that need clinical interpretation over time.
Source: Clinical genomics literature
How often should you test?
Test once — your genome doesn't change. The best moments are when you are well and can act on what a broad baseline shows, when family history points in several directions at once, and when you have clinical guidance lined up for interpreting broader results.
References
- PubMed literature — ACMG secondary-findings gene list and reporting recommendations.
- PubMed literature — prevalence of medically actionable variants in healthy population sequencing studies.
- MedlinePlus — Variants of uncertain significance: what they mean and how they are handled.
- MedlinePlus Genetics — Direct-to-consumer and clinical genomic screening: benefits and limitations.
Questions people actually ask
One collection. A lifelong baseline.
The broadest inherited-risk screen we offer, run in our own CLIA-certified laboratory.